Abstract 887P
Background
Locally advanced laryngeal carcinoma is treated by concomitant chemotherapy and radiotherapy then surgery whenever possible. Most patients between 60-70 years refuse surgery, therefore, we designed a treatment in order to postpone or evade the surgical option in elderly patients with T3 and T4 disease.
Methods
In this prospective phase II trial, we included 120 patients diagnosed with locally advanced laryngeal carcinoma (84 patients with T3 disease versus 36 patients with T4 disease) aged between (60-74 years) 67 years in median. Study was started by weekly paclitaxel at a fixed dose of 150mg and carboplatin AUC4 taken on days 1,8 and 15 of a 21-day schedule, cycles were repeated for 6 times. Then patients were evaluated by CT scan and laryngoscopy. Complete responders, partial and non-responders are referred to concomitant radiotherapy (60 Gy) with weekly cisplatin at 50mg for 6 weeks. Patients were followed up for a median of 42 months (38-57 months). Study end point was objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) for 3 years. Secondary end point was toxicity profile.
Results
ORR was observed in 116 patients (96.6%) evaluated by clinical exam, CT scan and laryngoscopy. Complete clinical response was documented in 87 patients after completion of chemotherapy 72.5% (95% CI: 66.2-79.1) and 27.5% partial responders (95% CI: 23.4-31.7). At 3 years of follow-up, PFS was 95% (95% CI: 92.7-98.8) (p value 0.001) while the OS at 3 years was 95%. We have lost 4 patients who died after hospitalization for severe neutropenia and renal failure. Surgery was deleted as an option in this category of patients. The toxicity profile was composed of different grades of neutropenia/thrombocytopenia and anemia. Reversable acute renal failure was seen in 5 patients as well as alopecia. Peripheral neuropathy with different grades was documented in 92 patients.
Conclusions
Neoadjuvant chemotherapy followed by concomitant chemo-radiotherapy in the light of feasibility and acceptable toxicity profile can be a substitution for surgery in elderly patients with locally advanced laryngeal carcinoma taking into consideration the good tolerance and the modest toxicity profile.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received anyfunding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
858P - Preoperative neoadjuvant chemoimmunotherapy for locally advanced head and neck squamous cell carcinoma patients: A prospective, single-arm, phase II clinical study
Presenter: Ping Han
Session: Poster session 02
861P - Neo-TIME trial: Neoadjuvant tislelizumab combined with albumin-paclitaxel, cisplatin, and fluorouracil(APF) in patients with locally advanced oral squamous cell carcinoma (LA-OSCC)
Presenter: Wenquan Zhao
Session: Poster session 02
862P - Neoadjuvant chemo-immunotherapy using carboplatin, nab-paclitaxel, oral metronomic therapy and low dose nivolumab for “borderline resectable” oral cavity carcinoma: A prospective phase II single-arm trial (NeoLOCUS)
Presenter: Praveen Kumar Marimuthu
Session: Poster session 02
863P - Safety and efficacy of four courses of pembrolizumab combined with carboplatin and albumin-binding paclitaxel versus two courses of neoadjuvant therapy in patients with resectable head and neck squamous cell carcinoma: An optimal efficacy study (prospective, two-arm, phase II)
Presenter: Jinsong Li
Session: Poster session 02
Resources:
Abstract
866P - Neoadjuvant and adjuvant AK104 in patients with recurrent, resectable squamous cell carcinoma of the head and neck: A phase II study
Presenter: Lei Liu
Session: Poster session 02
868P - Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Winston Wong
Session: Poster session 02